Drug

D0416 | Benoxaprofen

Molecular Formula C16H12ClNO3
Molecular Weight 301.72
Structure
State solid
Trade names Oraflex, Opren
Description nonsteroidal anti-inflammatory drug (NSAID)

M

M01AE06 Benoxaprofen


[M01AE] Propionic acid derivatives


[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS


[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS


[M] Musculoskeletal system


Toxicity Dose Time Species Model Method Action Positive criterion Reference
OXYGEN CONSUMPTION RATE (OCR) 30 μM 2 minutes human HepG2 Measurement of ECAR decrease EC50 7
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex I activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex IV activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex V activity Negative p < 0.05 3
ECAR > 100 μM 2 minutes human HepG2 Measurement of ECAR increase EC50 7

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 50 μM bovine heart mitochondria Measurement of complex I activity Negative p < 0.05 3
Succinate dehydrogenase 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
Quinol--cytochrome-c reductase 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
Cytochrome c oxidase 50 μM bovine heart mitochondria Measurement of complex IV activity Negative p < 0.05 3
ATP synthase 50 μM bovine heart mitochondria Measurement of complex V activity Negative p < 0.05 3

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]


H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P264, P270, P273, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
man TDLo oral 780mg/kg/13W- (780mg/kg) endocrine: gynecomastia British Medical Journal. Vol. 284, Pg. 1365, 1982.
women LDLo oral 780mg/kg/65D- (780mg/kg) liver: "jaundice, other or unclassified" Lancet. Vol. 1, Pg. 959, 1982.
rat LD50 intraperitoneal 129mg/kg (129mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981.
rat LD50 subcutaneous 121mg/kg (121mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981.
rat LD50 oral 118mg/kg (118mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981.
women TDLo oral 552mg/kg/46D- (552mg/kg) liver: "jaundice, other or unclassified" Lancet. Vol. 1, Pg. 959, 1982.
mouse LD50 oral 800mg/kg (800mg/kg) Journal of Medicinal Chemistry. Vol. 18, Pg. 53, 1975.
mouse LD50 subcutaneous 482mg/kg (482mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981.
women TDLo oral 168mg/kg/2W-I (168mg/kg) Nephron. Vol. 35, Pg. 279, 1983.
mouse LD50 intraperitoneal 398mg/kg (398mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981.

  • Not Available

  • ( -)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid ( -)-Benoxaprofen (+-)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
    (+-)-2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid (+-)-benoxaprofen (+/-)-2-(4-chlorophenyl)benzoxazole-5-propionic acid
    (.+/-.)-2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid (alphaR)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid
    (alphaS)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid 2-(2-(4-chlorophenyl)benzo[d]oxazol-5-yl)propanoic acid
    2-(4-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid
    2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid #
    2-[2-(4-chlorophenyl)benzooxazol-5-yl]propanoic acid 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl, (.+/-.)- 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl-
    5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl, (+-)- 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl- 51234-28-7
    67434-14-4 API0007668 BDBM50088388
    BRN 1085080 Benoxaprofen Benoxaprofen (USAN/INN)
    Benoxaprofen [USAN:INN:BAN] Benoxaprofene Benoxaprofene [INN-French]
    Benoxaprofeno Benoxaprofeno [INN-Spanish] Benoxaprofenum
    Benoxaprofenum [INN-Latin] C16H12ClNO3 CHEBI:76114
    CHEMBL340978 CTK2F8145 Compound 90459
    Coxigon D03080 DA-05331
    DB04812 DTXSID4022650 EINECS 257-069-7
    EINECS 266-692-3 FT-0662523 Inflamid
    LRCL 3794 LS-42081 Lilly 90459
    MITFXPHMIHQXPI-UHFFFAOYSA-N NSC 299582 NSC-299582
    NSC299582 Opren Oraflex
    Oraflex (TN) Q420082 SC-20578
    SCHEMBL24413 Uniprofen dl-Benoxaprofen

    DrugBank Name Benoxaprofen
    DrugBank DB04812
    CAS Number 51234-28-7, 67434-14-4
    PubChem Compound 39941
    KEGG Drug D03080
    PubChem.Substance 46508496
    ChEBI 76114
    PharmGKB PA166049178
    ChemSpider 36518
    BindingDB 50088388.0
    TTD DCL000338
    Wikipedia Benoxaprofen